Seattle Genetics Inc.

Eric Dobmeier joined Seattle Genetics in March 2002. He manages the company's business development, legal, corporate communications, strategic marketing and project management groups. While at Seattle Genetics, he has led negotiation and completion of multiple corporate alliances, including the worldwide license agreement with Genentech on SGN-40, the in-license of SGN-33 from PDL BioPharma and ADC collaborations with CuraGen, Progenics, Bayer, MedImmune and Agensys. He has also participated in raising over $200 million in equity financing for Seattle Genetics. Prior to joining the company, Mr. Dobmeier was with the law firms of Venture Law Group and Heller Ehrman White & McAuliffe, where he represented technology companies in connection with public and private financings, mergers & acquisitions and corporate partnering transactions. Mr. Dobmeier holds a law degree from Boalt Hall School of Law, University of California, Berkeley and an undergraduate degree from Princeton University.

Tom Reynolds joined Seattle Genetics in March 2007. As Chief Medical Officer, he leads clinical and regulatory activities across the company’s product portfolio. Dr. Reynolds has more than 15 years of biotechnology drug development experience, from preclinical development through the FDA approval process. Before joining Seattle Genetics, he was at Zymogenetics from 2002 to 2007, most recently as Vice President, Medical Affairs, where he oversaw the clinical development and BLA filing of rhThrombin and led the Medical Affairs department. Previously, he held various positions at Targeted Genetics including Vice President, Clinical Affairs, and before that was at Somatix Therapy (acquired by Cell Genesys in 1997). Dr. Reynolds holds a B.A. in Chemistry from Dartmouth College and both a Ph.D. in Biophysics and M.D. from Stanford University.

Todd Simpson joined Seattle Genetics in October 2005, bringing extensive industry experience from senior financial positions with several public biotechnology companies. Prior to joining Seattle Genetics, he served as Vice President of Finance and Administration and Chief Financial Officer at Targeted Genetics since October 2001. Previously, he was Vice President, Finance and Administration and Chief Financial Officer of Aastrom Biosciences. From 1992 to 1996, he served in financial roles at Integra Life Sciences Corporation and Telios Pharmaceuticals, Inc. (which was acquired by Integra in 1995). Mr. Simpson practiced public accounting with the firm of Ernst & Young LLP from 1983 to 1992, primarily focused in the life sciences and technology practices. He is a certified public accountant and received his B.S. in accounting and computer science from Oregon State University.

Morris Rosenberg joined Seattle Genetics in July 2001. Prior to joining the company, he was with Eli Lilly & Company (1998-2001), Biogen Incorporated (1990-1998) and Invitron Corporation (1987-1990). Dr. Rosenberg received a D.Sc. in Chemical Engineering, an M.S. and B.S. in Chemical Engineering, and a B.A. in Biology from Washington University in St. Louis, Missouri. While at Biogen he participated in the development of the manufacturing process for the multiple sclerosis treatment Avonex. Most recently at Eli Lilly, as Head of Cell Culture and Fermentation Development, Dr. Rosenberg led efforts in the development of several cell culture processes including for the sepsis therapeutic Xigris.

Vaughn Himes joined Seattle Genetics in April 2009, bringing more than twenty years of experience in manufacturing, technical operations, process development and scale-up activities. As Executive Vice President, Technical Operations, he oversees Seattle Genetics' manufacturing, supply chain and quality assurance and control functions. Previously, Dr. Himes was with Zymogenetics, Inc., most recently as Senior Vice President, Technical Operations where his responsibilities included commercial and clinical manufacturing, supply chain and logistics, quality control and process development. While at Zymogenetics, he oversaw the chemistry, manufacturing and control (CMC) portion of the successful Biologics License Application for Recothrom and managed its commercial supply. Previously, he held Vice President positions in manufacturing and development at Corixa, Targeted Genetics and Genovo. Dr. Himes received a Bachelor of Arts in Chemistry from Pomona College in California and a Ph.D. in Chemical Engineering from the University of Minnesota.

Christopher Pawlowicz joined Seattle Genetics in September 2008. He has more than 25 years of human resources experience principally in the pharmaceutical industry. Prior to Seattle Genetics, Mr. Pawlowicz was Senior Vice President, Human Resources and Administration at MedPointe Pharmaceuticals, a private equity-backed specialty pharma company where he was part of the turnaround team that successfully restructured and sold the business to Meda Pharmaceuticals. Before that, he was Corporate Vice President, Human Resources at Express Scripts, the nation’s third largest pharmacy benefit management company. Mr. Pawlowicz’s career has also included senior human resources positions at Pharmacia, Searle and Monsanto. Highlights include the global launch of Celebrex, the start up of biotechnology commercial teams in plant sciences, support of high growth commercial investments in Latin America, Europe and Asia, and the post-merger integration of numerous companies. He graduated summa cum laude with a B.A. in Economics from Benedictine College, and received his M.A., Labor and Industrial Relations from the University of Illinois – Urbana-Champaign.

Elaine Waller, PharmD, joined Seattle Genetics in September 2008, bringing more than 20 years of experience in regulatory affairs and clinical research. Prior to joining Seattle Genetics, Dr. Waller was with Sonus Pharmaceuticals, where she served as Senior Vice President, Regulatory Affairs/Quality Assurance and Clinical Research until its merger with OncoGenex Pharmaceuticals in August 2008. Before that, she was Chief Operating Officer at Radiant Research, a clinical site management organization. Dr. Waller’s previous experience includes senior positions in regulatory affairs and clinical research at Hoechst Marion Roussel and Marion Merrell Dow, predecessor companies to sanofi-aventis. She began her career in academia at the University of Texas at Austin where she held teaching positions in both graduate and undergraduate pharmacy education and was Assistant Director of Clinical Research at the Drug Dynamics Institute. Dr. Waller received a B.S. in Pharmacy and a Doctor of Pharmacy from the University of Missouri – Kansas City and an M.B.A. from Rockhurst College.

Iqbal Grewal joined Seattle Genetics in October 2004. He manages the company’s molecular oncology and immunology, translational biology and pharmacology and toxicology functions, including the planning and execution of studies to advance preclinical programs and support clinical development activities. Prior to joining Seattle Genetics, Dr. Grewal was with Genentech as a Senior Scientist in the Department of Immunology. He joined Genentech in May 1998, where he managed discovery research programs responsible for identifying and validating novel molecules for therapeutic use in the areas of oncology and autoimmune disease. In addition, he was a project leader on teams that conducted extensive studies of preclinical candidates for product development. Prior to Genentech, Dr. Grewal worked at Yale University School of Medicine. Before that, he held various research positions at the University of California, Los Angeles (UCLA). Dr. Grewal holds a B.S. in Biology and Chemistry from Panjab University in India, a M.S. in Immunobiology from the University of Aberdeen in the United Kingdom and a Ph.D. in Immunology from UCLA. He completed his post-doctoral fellowship at Howard Hughes Medical Institute at Yale University School of Medicine. Dr. Grewal is a fellow of the Royal College of Pathologists, London and a member of several distinguished societies. He has authored more than 100 scientific publications and is an author on numerous patent applications. Dr. Grewal serves on the editorial boards of research journals and has edited books on protein biologics.

Jonathan Drachman joined Seattle Genetics in November 2004. He oversees the activities involved in transitioning the company’s antibody-based therapeutics from preclinical into clinical development, including clinical pharmacology, bioanalytical development, experimental medicine and nonclinical science. Prior to joining Seattle Genetics, Dr. Drachman was Associate Professor in the Hematology Division, Department of Medicine at the University of Washington in Seattle, where he remains a Clinical Associate Professor of Medicine. He also served as Senior Investigator in the Division of Research and Education and Medical Director of the Umbilical Cord Blood Program at the Puget Sound Blood Center. Dr. Drachman received a B.A. in biochemistry from Harvard University and an M.D. from Harvard Medical School. He completed his residency in Internal Medicine and fellowship in Medical Oncology at the University of Washington in Seattle.

Peter Senter joined Seattle Genetics in August 1998 and has served as Vice President, Chemistry since September 2002. In February 2009, Dr. Senter was recognized as the company’s first Distinguished Fellow. He leads Seattle Genetics’ chemistry department, which carries out research in antibody-drug conjugate technologies, including the development of potent drug payloads, novel linker systems, conjugation methodology and mechanism of action studies. Prior to joining the company, Dr. Senter was with Cytokine Networks, Inc., the Bristol-Myers Squibb Pharmaceutical Research Institute and the Dana-Farber Cancer Institute, Harvard Medical School. Dr. Senter received a Ph.D. in Chemistry from the University of Illinois, and an A.B. in Biochemistry from the University of California, Berkeley. He is the Senior Editor of Bioconjugate Chemistry and serves on the Editorial Board of four scientific journals. Dr. Senter is an Affiliate Professor of Bioengineering at the University of Washington. His research interests include targeted drug delivery, protein chemistry and biochemistry, and anti-cancer drug design. Dr. Senter has authored more than 100 scientific publications and holds more than 20 patents.

Clay B. Siegall, Ph.D., co-founded Seattle Genetics in 1998 and is the company’s President, Chief Executive Officer and Interim Chairman of the Board of Directors. Under his leadership, Seattle Genetics has developed a diverse portfolio of clinical and preclinical product candidates targeting a variety of cancer and autoimmune indications. The company is also a leader in antibody technologies, notably its antibody-drug conjugate (ADC) platform. Dr. Siegall has guided Seattle Genetics’ capital-raising activities, securing more than $375 million through public and private financings, including the company’s initial public offering in 2001. In addition, the company has entered into multiple strategic collaborations, including an exclusive worldwide collaboration agreement with Genentech for dacetuzumab (SGN-40) valued at more than $860 million, and several ADC collaborations including with Genentech, MedImmune, CuraGen, Bayer, Progenics and Daiichi Sankyo that have generated more than $75 million since 2001. Prior to co-founding Seattle Genetics, Dr. Siegall was with the Bristol-Myers Squibb Pharmaceutical Research Institute from 1991 to 1997 and the National Cancer Institute, National Institutes of Health from 1988 to 1991. He serves on the Board of Directors of Alder BioPharmaceuticals, a private biotechnology company, and the Washington Biotechnology and Biomedical Association (WBBA), as well as on the Board of Governors of the Fred Hutchinson Cancer Research Business Alliance. He received a Ph.D. in Genetics from George Washington University and a B.S. in Zoology from the University of Maryland.

Eric Sievers joined Seattle Genetics in July 2006. He is responsible for directing, planning and executing clinical development activities of several of the company’s therapeutic programs. From 2003 to 2006, Dr. Sievers served as Medical Director at Zymogenetics supervising the oncology development of interleukin-21 and Atacicept. He performed his training in pediatric hematology and oncology at the University of Washington and the Fred Hutchinson Cancer Research Center, and served on the faculty of both institutions for over a decade. His academic research focused on improving treatment outcomes for patients with acute myeloid leukemia by defining the safety and efficacy of gemtuzumab ozogamicin (Mylotarg®) and evaluating novel flow cytometric techniques to predict leukemic recurrence. He is a member of the American Society of Hematology, American Society of Clinical Oncology and American Association for Cancer Research and is certified by the American Board of Pediatrics.

Dr. Felix J. Baker has served as a director of Neurogen Corporation since May 1999. Dr. Baker is a Managing Member of Baker Bros. Advisors, LLC, which he and his brother, Julian Baker, founded in 2000. Dr. Baker's firm manages Baker Brothers Investments, a family of long-term investment funds for major university endowments and foundations, which are focused on publicly traded life sciences companies. Dr. Baker's career as a fund-manager began in 1994 when he co-founded a biotechnology investing partnership with the Tisch Family. Dr. Baker holds a B.S. and a Ph.D. in Immunology from Stanford University, where he also completed two years of medical school. He is also a director of Conjuchem Inc., Seattle Genetics, Inc., and Trimeris, Inc.

Franklin M. Berger, CFA, has served as a Director of Seattle Genetics since June 2004 and is Chairman of the Audit Committee. Mr. Berger is a biotechnology industry analyst with over 25 years of experience in capital markets and financial analysis. He served most recently as Managing Director, Equity Research and Senior Biotechnology Analyst at J.P. Morgan Securities from 1998 to 2003. In this position, he initiated team coverage of 26 biotechnology companies and was responsible for technical, scientific and clinical due diligence as well as company selection. Previously, Mr. Berger served in similar capacities at Salomon Smith Barney from 1997 to 1998 and Josephthal & Co. from 1991 to 1997. Prior to his work as a biotechnology analyst, he managed Pantagruel Partners, a firm that developed early-stage pharmaceutical compounds for sale to drug companies and venture capital firms. He holds an M.B.A. from the Harvard Graduate School of Business Administration and an M.A. in International Economics and a B.A. in International Relations both from Johns Hopkins University. In addition to Seattle Genetics, Mr. Berger serves as a director of VaxGen, Inc., Isotechnika Inc. and Thallion Pharmaceuticals, all publicly-traded biopharmaceutical companies, and HealthShares, Inc., an investment company.

Bruce R. Blazar, M.D., has served in various academic positions at the University of Minnesota since 1978. Presently, he is a Professor in the Division of Pediatric Bone Marrow Transplantation, Director, Cytokine Reference Laboratory, Associate Director, Division of Pediatric Bone Marrow Transplantation and Andersen Chair in Transplantation Immunology. Dr. Blazar has received numerous professional honors and awards, including the American Cancer Society Clinical Fellowship Award, the NIH-NCI National Research Service Award and the MERIT Award. In addition to his past and present work on numerous editorial boards, he is a member of the FDA Advisory Committee on Biological Response Modifiers and the Leukemia and Lymphoma Society Translational Research Grant Committee. Dr. Blazar received a B.S. in biology at the Renssalear Polytechnic Institute and completed medical school in 1978 at Albany Medical College. He has multiple active grants that support a substantial research effort and has published over 230 manuscripts.

Mr. Welch has served as Chairman, Chief Executive Officer and President of the company and a member of the Board since May 2008, and as President and Chief Executive Officer of the company and a member of the Board since September 2003. From March 2003 to September 2003, Mr. Welch served as a consultant to Warburg Pincus LLC, a global private equity investment firm. From August 2002 to January 2003, Mr. Welch served as chairman and chief executive officer of Triangle Pharmaceuticals, Inc., a pharmaceutical company. From October 2000 to June 2002, Mr. Welch served as president of the pharmaceutical division of Elan Corporation, PLC. From September 1987 to August 2000, Mr. Welch served in various senior management roles at Sanofi (now Sanofi-Aventis) and its predecessor companies Sanofi and Sterling Winthrop. During his time at Sanofi-Aventis, he led the successful worldwide launches of Plavix®, Eloxatin® and Avapro® as Vice President of Worldwide Marketing and he served as COO of the U.S. business. From November 1980 to September 1987, Mr. Welch was with American Critical Care, a division of American Hospital Supply. Mr. Welch holds a B.S. from the University of Miami and an M.B.A. from the University of North Carolina.

Douglas E. Williams, Ph.D., 50, has served as a member of our Board of Directors since April 2004. He currently serves as President of ZymoGenetics, Inc. From September 2003 to August 2004, Dr. Williams served as Seattle Genetics' Chief Scientific Officer, Executive Vice President and a member of their Board of Directors. Prior to joining Seattle Genetics, from November 2002 to August 2003, Dr. Williams was Head of Health and Strategic Development for Genesis Research & Development, a biotechnology company located in New Zealand. From July to October 2002, he served as Senior Vice President, Washington Site Leader and a member of the Executive Committee for Amgen, Inc. Dr. Williams joined Amgen in July 2002 when it acquired Immunex Corporation, where he worked for 14 years, most recently serving as Executive Vice President, Chief Technology Officer and a member of Immunex's Board of Directors. Prior to his work at Immunex, Dr. Williams served on the faculty of the Indiana University School of Medicine and the Department of Laboratory Medicine at the Roswell Park Memorial Institute. He serves on the boards of privately-held Aerovance, Inc. and of publicly traded Anadys Pharmaceuticals, Inc. and is a member of the Scientific Advisory Board of Symphony Capital. Dr. Williams holds a B.S. magna cum laude in Biological Sciences from the University of Massachusetts, Lowell and a Ph.D. in Physiology from the State University of New York at Buffalo, Roswell Park Division.

Mr. McLaughlin is a co-founder of PEAK Surgical and has served on our board of directors since inception. He is currently the Chief Executive Officer of Anesiva, Inc. Prior to Anesiva, Mr. McLaughlin was President of Tularik, Inc. and held many other senior management positions including Executive Vice President of Genentech, Inc. He is a co-founder of Eyetech Pharmaceuticals, Inc. where he served as the Chairman of the Board. He also served on the board of directors of IDEC Pharmaceuticals, Inc.

Marc Estes Lippman, M.D. lippmanm@umich.edu has been a senior advisor to Perseus for ten years and will devote up to 15% of his time to working with Perseus on biotechnology strategy. Dr. Lippman is the John G. Searle Professor and Chief of Medicine at the University of Michigan Health System. Prior to his current appointments, Dr. Lippman held a number of positions at Georgetown University Medical Center, including Director of the Lombardi Cancer Research Center, Professor and Chairman of the Department of Oncology, Professor of Medicine, and Chief of the Division of Hematology-Oncology. He also served as Head of the Medical Breast Cancer Section of the Medicine Branch of the National Cancer Institute.

William J. Murphy, Ph.D., is a Professor in the Microbiology and Immunology department at the University of Nevada School of Medicine in Reno. His research is focused on examining means to improve the efficacy of bone marrow transplantation (BMT) in cancer and other diseases. In addition, his laboratory has been examining BMT as a means to understand the immune system and the process of aging as well as on improving immune resistance to opportunistic infections that can arise after a transplant. Dr. Murphy is also the Director of Basic Research of the newly established Nevada Cancer Institute in Las Vegas and is a Guest Researcher at the National Cancer Institute, where he also maintains a laboratory. Dr. Murphy earned his B.S. in Biology at Rutgers University followed by his Ph.D. in Immunology from the University of Texas Southwestern Medical School in 1989. He did a post-doctoral fellowship under Dr. Dan Longo, then Director of the Biological Response Modifiers Program at the National Cancer Institute (NCI) at Frederick. He became Principal Investigator and Section Head of the Transplantation Biology Laboratory in 1996. In 2000, he became Director of Basic Research of SAIC Frederick at the NCI with a directorate consisting of over 250 scientific personnel and an operating budget of over 30 million dollars. In 2002, Dr. Murphy joined the University of Nevada. He was awarded the American Cancer Society Scholar Award for his research on immunotherapy and BMT in 2002. He currently serves on the editorial boards for Blood, Experimental Hematology, Clinical Immunology, and Biology of Blood and Bone Marrow Transplantation. He also is an ad-hoc member of several study sections at NIH. He is Honorary Scientific Director of the Shandong Cancer Biotherapy Center in P.R. China as well as Honorary Research Professor at the Institute of Biomedical Sciences. He has published over 160 articles in scientific journals and holds several patents concerning immunotherapy in cancer.